Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin A Hutchison

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Nature Reviews. Nephrology|February 22, 2012
Novel approaches for reducing free light chains in patients with myeloma kidneyColin A Hutchison, Joan Bladé, Paul Cockwell, et al.
Kidney Medicine|May 2, 2022
Medium Cutoff Versus High-Flux Hemodialysis Membranes and Clinical Outcomes: A Cohort Study Using Inverse Probability Treatment WeightingAlejandra P Molano, Colin A Hutchison, Ricardo Sanchez, et al.
Journal of Clinical Pathology|September 30, 2010
Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidneyKolitha Basnayake, Chee Kay Cheung, Michael Sheaff, et al.
Journal of the American Society of Nephrology : JASN|April 23, 2011
Early reduction of serum-free light chains associates with renal recovery in myeloma kidneyColin A Hutchison, Paul Cockwell, Stephanie Stringer, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 3, 2009
Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysisColin A Hutchison, Arthur R Bradwell, Mark Cook, et al.
Mayo Clinic Proceedings|May 7, 2014
Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney diseaseColin A Hutchison, Anne Burmeister, Stephen J Harding, et al.
The Lancet. Haematology|March 16, 2019
High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trialColin A Hutchison, Paul Cockwell, Veronica Moroz, et al.
Journal of the American Society of Nephrology : JASN|January 19, 2007
Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studiesColin A Hutchison, Paul Cockwell, Steven Reid, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 24, 2010
The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathiesRichard Fish, Jennifer Pinney, Poorva Jain, et al.
Mayo Clinic Proceedings|November 6, 2017
The Association of Serum Free Light Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta-analysisSimon D S Fraser, Anthony Fenton, Scott Harris, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Nature Reviews. Nephrology|February 22, 2012
Novel approaches for reducing free light chains in patients with myeloma kidneyColin A Hutchison, Joan Bladé, Paul Cockwell, et al.
Kidney Medicine|May 2, 2022
Medium Cutoff Versus High-Flux Hemodialysis Membranes and Clinical Outcomes: A Cohort Study Using Inverse Probability Treatment WeightingAlejandra P Molano, Colin A Hutchison, Ricardo Sanchez, et al.
Journal of Clinical Pathology|September 30, 2010
Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidneyKolitha Basnayake, Chee Kay Cheung, Michael Sheaff, et al.
Journal of the American Society of Nephrology : JASN|April 23, 2011
Early reduction of serum-free light chains associates with renal recovery in myeloma kidneyColin A Hutchison, Paul Cockwell, Stephanie Stringer, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 3, 2009
Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysisColin A Hutchison, Arthur R Bradwell, Mark Cook, et al.
Mayo Clinic Proceedings|May 7, 2014
Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney diseaseColin A Hutchison, Anne Burmeister, Stephen J Harding, et al.
The Lancet. Haematology|March 16, 2019
High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trialColin A Hutchison, Paul Cockwell, Veronica Moroz, et al.
Journal of the American Society of Nephrology : JASN|January 19, 2007
Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studiesColin A Hutchison, Paul Cockwell, Steven Reid, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 24, 2010
The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathiesRichard Fish, Jennifer Pinney, Poorva Jain, et al.
Mayo Clinic Proceedings|November 6, 2017
The Association of Serum Free Light Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta-analysisSimon D S Fraser, Anthony Fenton, Scott Harris, et al.
Pageof 5